Oligonucleotide Therapy Global Market To Reach Value Of About $2 Billion In 2025

25 Oct, 2021

The oligonucleotide therapy market consists of sales of oligonucleotide therapy related services by entities (organizations, sole traders and partnerships) that manufacture oligonucleotide therapy products. Oligonucleotide therapy uses synthetic oligonucleotides, which can be artificially produced in labs, to inactivate disease-causing genes. Only goods and services traded between entities or sold to end consumers are included.

Global Oligonucleotide Therapy Market Size And Drivers:

The global oligonucleotide therapy market is expected to grow from $0.88 billion in 2020 to $0.98 billion in 2021 at a compound annual growth rate (CAGR) of 11.4%. The growth is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The market is expected to reach $1.62 billion in 2025 at a CAGR of 13%. The rise in the number of cancer cases across the globe is likely to contribute to the growth of the oligonucleotide therapy market during the forecast period.

Request For A Sample For The Global Oligonucleotide Therapy Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=3398&type=smp

Trends In The Global Oligonucleotide Therapy Market

The developers and providers of the oligonucleotide therapy market are investing in research and development to remodel the design of therapy to reduce its side effects on patients. The new and innovative oligonucleotides allow precision medicine approaches and can be designed to selectively target any gene with minimal side effects. It also helps in targeting patient-specific sequences that are causative of rare diseases. In August 2020, FDA granted accelerated approval to Viltepso (viltolarsen) injection, an antisense oligonucleotide for the treatment of Duchenne muscular dystrophy (DMD), which is a genetic disorder, with reduced side effects.

Global Oligonucleotide Therapy Market Segments:
The global oligonucleotide therapy market is further segmented –
By Type: Antisense Oligonucleotide, Aptamer, Other
By Application: Infectious Diseases, Oncology, Neurodegenerative Disorders, Cardiovascular Diseases, Kidney Diseases, Others
By End User: Hospitals, Research Institutes
By Geography: The global oligonucleotide therapy market is segmented into North America, South America, Asia-Pacific, Eastern Europe, Western Europe, Middle East and Africa.

Read More On The Report For The Global Oligonucleotide Therapy Market At:

https://www.thebusinessresearchcompany.com/report/oligonucleotide-therapy-market-global-report-2020-30-covid-19-growth-and-change

Oligonucleotide Therapy Global Market Report 2021 is one of a series of new reports from The Business Research Company that provides oligonucleotide therapy market overviews, analyzes and forecasts market size and growth for the global oligonucleotide therapy market, oligonucleotide therapy market share, oligonucleotide therapy market players, oligonucleotide therapy market segments and geographies, oligonucleotide therapy market’s leading competitors’ revenues, profiles and market shares. The oligonucleotide therapy market report identifies top countries and segments for opportunities and strategies based on market trends and leading competitors’ approaches.